Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
QL-415 by QLSF Biotherapeutics for Hematological Tumor: Likelihood of Approval
QL-415 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Hematological Tumor. According to GlobalData, Phase...
QL-401 by QLSF Biotherapeutics for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
QL-401 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...
QL-401 by QLSF Biotherapeutics for Refractory Acute Myeloid Leukemia: Likelihood of Approval
QL-401 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...
QL-401 by QLSF Biotherapeutics for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
QL-401 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According to...
QL-401 by QLSF Biotherapeutics for Solid Tumor: Likelihood of Approval
QL-401 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
QL-401 by QLSF Biotherapeutics for Myelodysplastic Syndrome: Likelihood of Approval
QL-401 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...
QL-335 by QLSF Biotherapeutics for Colorectal Cancer: Likelihood of Approval
QL-335 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...